Associations between insulin pump self‐management and HbA1c in type 1 diabetes

Insulin pump self‐management is important for glycaemic outcomes. We aimed to investigate associations between self‐management factors and HbA1c.

[1]  B. Cleal,et al.  Insulin Pump Treatment in Adults with Type 1 Diabetes in the Capital Region of Denmark: Design and Cohort Characteristics of the Steno Tech Survey , 2021, Diabetes Therapy.

[2]  J. Wiens,et al.  Association Between Management of Continuous Subcutaneous Basal Insulin Administration and HbA1C , 2021, Journal of diabetes science and technology.

[3]  K. Bell,et al.  Insulin pump dosing strategies for meals varying in fat, protein or glycaemic index or grazing-style meals in type 1 diabetes: a systematic review. , 2020, Diabetes research and clinical practice.

[4]  Lauge Neimann Rasmussen,et al.  Education programmes for persons with type 1 diabetes using an insulin pump: A systematic review , 2020, Diabetes/metabolism research and reviews.

[5]  Roman Hovorka,et al.  Training and Support for Hybrid Closed-Loop Therapy , 2020, Journal of diabetes science and technology.

[6]  K. Bennett,et al.  Low uptake of continuous subcutaneous insulin infusion therapy in people with type 1 diabetes in Ireland: a retrospective cross-sectional study , 2020, BMC Endocrine Disorders.

[7]  Jennifer M. Trujillo,et al.  Effects of Diabetes Numeracy on Glycemic Control and Diabetes Self-Management Behaviors in Patients on Insulin Pump Therapy , 2019, Diabetes Therapy.

[8]  David M Maahs,et al.  State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. , 2019, Diabetes technology & therapeutics.

[9]  H. Bilo,et al.  Mealtime insulin bolus adherence and glycemic control in adolescents on insulin pump therapy , 2018, European Journal of Pediatrics.

[10]  K. Barnard,et al.  Diabetes Technological Revolution: Winners and Losers? , 2018, Journal of diabetes science and technology.

[11]  R. Rabasa-Lhoret,et al.  Duration of Catheter Use in Patients with Diabetes Using Continuous Subcutaneous Insulin Infusion: A Review. , 2018, Diabetes technology & therapeutics.

[12]  S. Amiel,et al.  Optimal prandial timing of bolus insulin in diabetes management: a review , 2017, Diabetic medicine : a journal of the British Diabetic Association.

[13]  Diana Naranjo,et al.  Diabetes Device Use in Adults With Type 1 Diabetes: Barriers to Uptake and Potential Intervention Targets , 2016, Diabetes Care.

[14]  V. Franklin.  Influences on Technology Use and Efficacy in Type 1 Diabetes , 2016, Journal of diabetes science and technology.

[15]  S. Gudbjörnsdottir,et al.  Durability of oral hypoglycemic agents in drug naïve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR) , 2015, BMJ Open Diabetes Research and Care.

[16]  Bruce W Bode,et al.  Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[17]  B. Olsen,et al.  The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial , 2012, Diabetologia.

[18]  J. DeVries,et al.  Premeal Injection of Rapid-Acting Insulin Reduces Postprandial Glycemic Excursions in Type 1 Diabetes , 2010, Diabetes Care.

[19]  I. Hirsch.  Practical pearls in insulin pump therapy. , 2010, Diabetes technology & therapeutics.

[20]  H Peter Chase,et al.  Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. , 2010, Diabetes technology & therapeutics.

[21]  The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. , 1996, Diabetes.